5 results
·
72ms
·
Sources: EU EUDAMED, US FDA
AIM-V (R) MEDIUM, MODEL 087-0112
FDA 510(k)
FDA Class 2
·Gastroenterology, Urology
Chromogenic In Situ Hybridization, Nucleic Acid Amplification, Her2/Neu Gene, Breast Cancer
FDA Pre-Market Approval
FDA Class 3
·SPOT-LIGHT HER2 CISH KIT
Chromogenic In Situ Hybridization, Nucleic Acid Amplification, Her2/Neu Gene, Breast Cancer
FDA Pre-Market Approval
FDA Class 3
·SPOT-LIGHT HER2 CISH KIT
Chromogenic In Situ Hybridization, Nucleic Acid Amplification, Her2/Neu Gene, Breast Cancer
FDA Pre-Market Approval
FDA Class 3
·SPOT-LIGHT HER2 CISH KIT
Chromogenic In Situ Hybridization, Nucleic Acid Amplification, Her2/Neu Gene, Breast Cancer
FDA Pre-Market Approval
FDA Class 3
·SPOT-LIGHT HER2 CISH KIT